(Q43639290)

25 November 2017

title

Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration (English)

1 reference

25 November 2017

1 reference

D Y Mitchell

1

1 reference

25 November 2017

W H Barr

2

1 reference

25 November 2017

R A Eusebio

3

1 reference

25 November 2017

K A Stevens

4

1 reference

25 November 2017

F P Duke

5

1 reference

25 November 2017

D A Russell

6

1 reference

25 November 2017

J D Nesbitt

7

1 reference

25 November 2017

J H Powell

8

1 reference

25 November 2017

G A Thompson

9

1 reference

25 November 2017

publication date

1 February 2001

1 reference

25 November 2017

published in

Pharmaceutical Research

1 reference

25 November 2017

volume

18

1 reference

25 November 2017

issue

2

1 reference

25 November 2017

page(s)

166-170

1 reference

Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique.

25 November 2017

cites work

1 reference

12 December 2020

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

1 reference

12 December 2020

Clodronate kinetics and bioavailability

1 reference

12 December 2020

Clodronate kinetics and dynamics

1 reference

12 December 2020

Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis

1 reference

12 December 2020

Human pharmacokinetics of tiludronate

1 reference

12 December 2020

Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data

1 reference

12 December 2020

Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers

1 reference

12 December 2020

Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis

1 reference

12 December 2020

Studies of the oral bioavailability of alendronate.

1 reference

12 December 2020

The effect of dosing regimen on the pharmacokinetics of risedronate

1 reference

12 December 2020

Risedronate gastrointestinal absorption is independent of site and rate of administration

1 reference

12 December 2020

Statistical estimations in pharmacokinetics.

1 reference

12 December 2020

Evaluation of orally administered highly variable drugs and drug formulations

1 reference

12 December 2020

Effect of renal function on risedronate pharmacokinetics after a single oral dose

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Antiresorptive dose-response relationships across three generations of bisphosphonates

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1011024200280

1 reference

25 November 2017

1 reference